Lundbeckfonden Ventures-backed Trevi has filed for an $86.2m IPO to fund clinical trials for pruritus-focused drug treatments.

Trevi Therapeutics, the US-based pruritus treatment developer backed by pharmaceutical firm Lundbeck, has filed to raise up to $86.2m in an initial public offering.

Founded in 2011, Trevi is developing an oral therapy called Nalbuphine ER, which is designed to treat a severe form of itching called pruritus in addition to chronic coughing caused by neurologically mediated conditions.

Part of the IPO proceeds will be used to fund an ongoing phase 1b clinical trial for Nalbuphine ER in patients…